Plain-English translation of NCT06251388 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new immunotherapy drug called cadonilimab () in women with advanced cervical cancer. You would first receive standard treatment with radiation and chemotherapy together, and then, if your cancer doesn't get worse, you would receive cadonilimab as a follow-up treatment. The study wants to see if adding this medication helps fight the cancer more effectively.
Advanced cervical cancer is serious and hard to treat with standard approaches alone. This medication is designed to help your immune system recognize and attack cancer cells, and researchers believe it may improve outcomes when used after radiation and chemotherapy.
You likely qualify if…
You likely don't qualify if…
You would first receive standard concurrent radiation and chemotherapy treatment at your hospital. Once you complete this and your cancer has not progressed, you would then receive the new medication as an intravenous infusion every three weeks. You would continue this medication for up to one year, unless your cancer gets worse or you experience side effects that are too difficult to tolerate. Throughout the study, you will have regular visits to monitor how you are responding and to check for any side effects.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
West China Second University Hospital
Collaborators
Affiliated Hospital of North Sichuan Medical College, The Affiliated Hospital Of Southwest Medical University
Enrollment target
~50 participants
Started
February 2024
Primary completion
May 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Sex
Female only
Last updated on clinicaltrials.gov in February 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Rutie Yin, Clinical Professor
West China Second University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.